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Prevalence of fatigue in Parkinson disease
and its clinical correlates
ABSTRACT
Objective: To assess in a noninterventional setting the prevalence and severity of fatigue in pa-
tients with Parkinson disease (PD).
Methods: This was a cross-sectional study conducted in Italian patients with PD. Objectives
included the evaluation of the current prevalence and severity of fatigue in patients with PD
measured using the 16-item Parkinson Fatigue Scale (PFS-16), distressing fatigue (defined as
a PFS-16 mean score $3.3), and assessment of its clinical correlates.
Results: A total of 402 patients were enrolled and 394 patients completed the PFS-16 question-
naire with a PFS-16 mean (6SD) score of 2.876 0.99. Of these, 136 patients (33.8%) reported
distressing fatigue (PFS-16 mean score $3.3). Patients with distressing fatigue were older (p 5
0.044) and had a longer duration of PD (p , 0.0001) than those without distressing fatigue. The
presence of distressing fatigue was associated with higher total Unified Parkinson’s Disease
Rating Scale (UPDRS) scores, poorer quality of life (39-item Parkinson’s Disease Questionnaire
[PDQ-39]), worse social and psychological behaviors, a higher severity of depressive symptoms,
and a higher prevalence of sleep disorders (all p , 0.001). Logistic regression analyses revealed
that higher total UPDRS scores, female sex, depression, sleep disorders, as well as higher UPDRS
activities of daily living scores and PDQ-39 mobility scores increase the likelihood of distressing
fatigue in patients with PD.
Conclusions: Approximately one-third of patients with PD have distressing fatigue, which is sig-
nificantly associated with depression and sleep disorders. The fact that the presence of fatigue
worsens patient quality of life supports the need to better diagnose and treat this debilitating
symptom. Neurology® 2014;83:215–220
GLOSSARY
DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ICD-10 5 International Classification of
Diseases, 10th revision; MAO-B 5 monoamine oxidase B; MS 5 multiple sclerosis; PD 5 Parkinson disease; PDQ-39 5
39-item Parkinson’s Disease Questionnaire; PDSS5 Parkinson’s Disease Sleep Scale; PFS-165 16-item Parkinson Fatigue
Scale; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Fatigue is a nonspecific symptom common to several CNS disorders. According to ICD-10,
signs and symptoms of fatigue include asthenia, debility, general physical deterioration, lethargy,
and tiredness.1 Although previously overlooked in Parkinson disease (PD), fatigue is now
accepted to be one of the most common PD symptoms with a reported prevalence between
33% and 58%.2 Not only is the prevalence of fatigue higher than the age-matched population,3
the fatigue experienced in PD seems to be qualitatively different from that experienced by the
general population.2,4 Fatigue is often considered by patients with PD to be one of the most
disabling symptoms affecting daily activities5,6 and quality of life.7–10
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Despite the advances made in our under-
standing of fatigue in PD, several important
questions remain. First, what is the prevalence
of this symptom in patients with PD treated in
routine clinical practice? Most studies have
been limited in size and inclusion criteria,
and have not had fatigue as the focus of the
investigation. Moreover, previous studies have
not consistently evaluated the severity of the
fatigue. Second, little is known about whether
there are any clinical correlates that may be
associated with the presence of fatigue. For
example, whereas a number of studies did
not find any direct relationship between dis-
ease severity and fatigue,11,12 others indicate
that the severity of the fatigue increases with
disease progression.13,14 The aims of this study
were to assess, in a noninterventional epidemi-
ologic setting, the prevalence and severity of
fatigue in patients with PD and its clinical
correlates.
METHODS Standard protocol approvals, registrations,
and patient consents. This was an observational, cross-
sectional, multicenter study, conducted in 27 sites in Italy
between March and June 2011. The study protocol was
approved by the ethics committee of the coordinating center
(Comitato Etico dell IRCCS San Raffaele Pisana, Rome, Italy)
and by the reference local ethic committees of each of the
participating sites. The study was undertaken in accordance
with Good Clinical Practice and the provisions of the
International Conference on Harmonization, with all patients
providing written informed consent.
Patients. To emulate the real-world general PD population, this
study recruited outpatients (male or female, aged 18 years or
older) with a confirmed diagnosis of idiopathic PD according to
Brain Bank diagnostic criteria,15 attending routine neurology
clinics at the participating sites. Patients could be receiving any
medication for PD and comorbidities. Exclusion criteria included
the following: any type of dementia (DSM-IV criteria), congestive
heart failure, other severe cardiopathy, severe liver disease/cirrhosis,
severe renal insufficiency/dialysis, severe respiratory insufficiency,
and other conditions known to cause or influence fatigue, including
severe anemia, severe hypothyroidism, and severe diabetes (severity
according to investigator judgment, no cutoff values specified).
Assessments. The study plan included a single visit during
which all information was collected. Clinical data included
patient demographics, medical history (onset and duration of
PD), presence of comorbidities and associated treatments, sever-
ity of PD according to the modified Hoehn and Yahr scale, sever-
ity of key motor symptoms (resting tremor, rigidity, bradykinesia,
gait disturbance) as assessed by the Unified Parkinson’s Disease
Rating Scale (UPDRS, version 3) during the on phase, total
UPDRS scores (sum of parts I, II, and III), quality of life as
assessed by the 39-item Parkinson’s Disease Questionnaire
(PDQ-39) and the Psychological Well-being Scale, depression
assessed by the Beck Depression Inventory, and sleep disorders
assessed by the Parkinson’s Disease Sleep Scale (PDSS).
Fatigue was assessed using the 16-item Parkinson’s Fatigue
Scale (PFS-16), which was developed for use in routine clinical
practice and has been recommended for screening and suggested
for rating the severity of fatigue.16,17 The PFS is a 16-item,
patient-rated scale that encompasses the physical aspects of
fatigue and their impact on patients’ daily functioning. Item
scores range from 1 (strongly disagree) to 5 (strongly agree), with
the PFS-16 mean score being calculated as the mean of all indi-
vidual item scores (range: 1.0–5.0).16 During the development
process, the scale developers found that a threshold PFS-16 mean
score $3.3 was able to differentiate between patients who per-
ceived their fatigue to be distressing (patients were asked if they
found their fatigue to be a problem) and those who did not find
their fatigue to be distressing with a sensitivity of 84.7% and a
specificity of 82.1%.17 In accordance with this finding, we used a
threshold PFS-16 mean score of 3.3 to define the presence of
distressing fatigue in our study.
Statistical analysis. The sample size of at least 380 patients for
this study was estimated according to the number of exploratory
variables clinically relevant to be included in the logistic regres-
sion analysis (number of subjects 5 [number of variables 3
10]/event rate) plus a 20% missing data rate in the covariance
data matrix. There were 9 exploratory variables included in the
multivariate analysis and the estimation assumed that the rate of
patients with a significant correlation between the degree of
fatigue (PFS-16 score) and the PD severity (Hoehn and Yahr
score) would be $30%.
Data analyses were performed in the overall evaluable popula-
tion defined as all patients enrolled in the study. Continuous vari-
ables were summarized by descriptive statistics and categorical
variables were summarized using counts of patients and percen-
tages. Comparisons between patients with and without fatigue were
made using x2 test or Fisher exact test for qualitative variables and
the nonparametric Mann-Whitney test for quantitative variables.
A preplanned logistic regression analysis was used to assess the
factors associated with fatigue in PD; confidence intervals were
derived using the Wald method. A binary dependent variable
of fatigue was assigned a value of 0 when the PFS-16 mean score
was,3.3 and value of 1 when the score was$3.3. The following
preplanned covariates were included in the logistic model: age,
sex, marital status (married vs other status), duration of PD, total
UPDRS score, severity of PD (Hoehn and Yahr stages 1–2 vs
stages 3–4), depression (presence vs absence), sleep disorders
(presence vs absence), and daytime sleepiness (item 15 of the
PDSS; presence vs absence). In addition, a second post hoc logis-
tic regression analysis was performed that included all of the
variables of the first model plus PDSS, UPDRS, PDQ-39, and
Beck Depression Inventory questionnaire scores, age at PD diag-
nosis, and geographical area. A backward procedure with a cutoff
of p 5 0$10 was applied to select the variables that were to be
removed from the model.
No missing data were replaced. All statistical tests were per-
formed at the p # 0.05 level (2-sided). Statistical analyses were
performed using the SAS System version 9.2 (SAS Institute, Cary,
NC).
RESULTS Total population. A total of 402 patients
were screened and all were eligible for inclusion into
the study; the main patient demographic and clinical
characteristics are summarized in table 1. The study
cohort included more men than women (60.9% vs
39.1%) and a large proportion of patients (37.6%)
were older than 70 years. Approximately three-quarters
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of patients (73.6%) were in Hoehn and Yahr stages 1–2
and all but one patient were taking antiparkinsonian
medication. The majority of patients received
treatment with levodopa and/or a dopamine agonist;
9 patients (3.5%) were receiving monoamine oxidase B
(MAO-B) monotherapy. In addition, 30 patients
received concomitant antidepressants (mostly selective
serotonin reuptake inhibitors) and 21 patients were
being treated with amantadine.
Presence of fatigue.Overall, 394 patients completed the
PFS-16 questionnaire; of these, 136 patients (33.8%)
reported distressing fatigue (PFS-16 mean score $3.3
points). For the total population, the mean6 SD PFS-
16 score was 2.87 6 0.99. In patients with distressing
fatigue, mean scores for all PFS-16 items were higher
than 3.3. The items with the highest mean score were as
follows: “Because of fatigue, it takes me longer to get
things done,” “I get tired more quickly than other
people I know,” “If I was not so tired, I could do
more things,” and “I have to rest during the day.”
Fatigue vs nonfatigue subgroup comparisons. Compari-
sons between patients with distressing fatigue vs those
without distressing fatigue showed that patients with
distressing fatigue were older (68.0 6 9.2 vs 66.3 6
8.7 years; p5 0.044) and had a longer duration of PD
(9.1 6 6.4 vs 6.6 6 5.0 years; p , 0.001). However,
the mean age at diagnosis did not differ between the
2 subgroups. Marital status had no significant effect on
the presence of distressing fatigue; however, the distri-
bution of educational level by category of fatigue
showed that patients with lower educational status (no
education or secondary school level) were more likely to
have a PFS-16 mean score $3.3 points (35.3%
and 36.0%, respectively) than a score ,3.3 points
(26.4% and 29.1%, respectively). Conversely, patients
with a high school or university education were more
predominant among those with a PFS-16 mean score
,3.3 points (31.4% and 13.2%, respectively) than
among those with a score $3.3 points (21.3% and
7.4%, respectively). The difference in the distribution
of educational level between fatigue subgroups was
statistically significant (p 5 0.021).
The presence of distressing fatigue was associated
with increased total UPDRS scores, a poorer quality
of life, worse sensations of psychological well-being, a
higher severity of depressive symptoms, and a higher
prevalence of sleep disorders (nocturnal sleep problems
and daytime sleepiness) (table 2). Further analysis of
each of the key UPDRSmotor symptoms revealed that
patients with distressing fatigue had higher scores for
all motor symptoms assessed (p , 0.001), with the
exception of tremor at rest and rigidity in the lower
joints. Similarly, patients with distressing fatigue were
more likely to have mild to moderate or moderate to
severe depressive symptoms, while patients without
distressing fatigue were more likely to have absence/
denial of or minimal depressive symptoms (p ,
0.001). Patients with distressing fatigue were also more
likely to have very severe, severe, or moderate daytime
sleep disorders, while patients without distressing
fatigue were more likely to have mild/absent daytime
sleep disorders (p , 0.001).
There were no substantial differences in PFS-16
mean scores when comparing patients taking differ-
ent antiparkinsonian medications. However, a review
(descriptive data only) of the different treatment com-
binations indicated that there was a lower proportion
Table 1 Demographic and clinical characteristics of the total sample
Characteristic Value
Age, y (n 5 402), mean 6 SD (range) 66.9 6 8.9 (37–89)
Duration of PD, y (n 5 394), mean 6 SD (range) 7.5 6 5.6 (1–40)
PFS-16 score (n 5 394), mean 6 SD (range) 2.87 6 0.99 (1–5)
Sex (n 5 402), women; men, n (%) 157 (39.1); 245 (60.9)
Hoehn and Yahr stage (n 5 402), n (%)
1 94 (23.4)
2 202 (50.2)
3 96 (23.9)
4 10 (2.5)
Education, n (%)
None/first level 116 (29.4)
Secondary level 124 (31.5)
High school 110 (27.9)
University 44 (11.2)
Current PD medications (n 5 394), n (%)
Not treated 1 (0.3)
Amantadine 21 (5.3)
Anticholinergics 13 (3.3)
COMT inhibitors 100 (25.4)
Dopamine agonists 280 (71.1)
Levodopa 306 (77.7)
MAO-B inhibitors 153 (38.8)
Comorbidities >5% of evaluable population (n 5 394), n (%)
Any 278 (70.6)
Hypertension 143 (36.3)
Depression 46 (11.7)
Benign prostatic disordera 39 (15.9)
Hypercholesterolemia 29 (7.4)
Diabetes mellitus 26 (6.6)
Cardiomyopathy 21 (5.3)
Abbreviations: COMT 5 catechol-O-methyltransferase; MAO-B 5 monoamine oxidase B;
PD 5 Parkinson disease; PFS-16 5 16-item Parkinson’s Fatigue Scale.
The total sample includes 402 patients, 394 of whom completed the PFS-16.
aMen only.
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of patients taking levodopa plus an MAO-B inhibitor
(n 5 100) in the fatigued vs nonfatigued subgroup
(19.9% vs 28.4%) and also of patients taking a dopa-
mine agonist plus an MAO-B inhibitor (n 5 103)
(18.4% vs 31.1%). There was no substantial differ-
ence in the proportion of patients with or without
distressing fatigue taking levodopa plus a dopamine
agonist (n 5 194) (52.9% vs 47.5%), but the pro-
portion of patients taking levodopa plus the COMT
(catechol-O-methyltransferase) inhibitor entacapone
(n 5 100) appeared to be higher in the fatigued vs
nonfatigued group (33.1% vs 21.4%).
The proportion of patients with concomitant dis-
eases was slightly higher in patients with distressing
fatigue vs those without distressing fatigue (73.5% vs
69.0%), but this difference was not significant (p 5
0.416). However, the 2most common diseases—arterial
hypertension and depression—were more prevalent in
patients with distressing fatigue than in those without
distressing fatigue (44.1% vs 32.2% for hypertension,
and 16.2% vs 9.3% for depression, respectively).
Factors associated with fatigue. Preplanned logistic
regression analysis (n 5 343) showed that total
UPDRS scores, female sex, the presence of depres-
sion, and the presence of sleep disorders significantly
increased the odds of having distressing fatigue in
patients with PD (table 3). In the second analysis,
performed post hoc (n5 319), higher UPDRS activ-
ities of daily living and worse PDQ-39 mobility
scores (and none of the other factors analyzed) were
found to be predictive of fatigue in PD.
DISCUSSION The results of this large Italian study
confirm that fatigue is common in outpatients with
PD being treated in routine practice and is considered
distressing (defined as PFS-16 mean score $3.3
points) in approximately one-third of them. Subgroup
comparisons showed that the presence of distressing
fatigue was associated with increased disease severity, a
poorer quality of life, worse social and psychological
behaviors, a higher severity of depressive symptoms,
and a higher prevalence of nocturnal sleep disorders
and daytime sleepiness.
The prevalence of fatigue in patients with PD in
this study appears somewhat lower than that observed
in most other studies.4,8,11,18 However, the literature
shows a wide range of prevalence of fatigue in PD
according to the different definitions of fatigue and
the populations tested. Unlike other surveys, which
simply looked for the presence and absence of this
symptom, our study purposefully used a higher cutoff
score (PFS-16 mean score of 3.3) to better identify
the prevalence of fatigue that patients with PD find
“distressing.”17 This probably lowered the percentage
measured. Fatigue is a subjective experience; what
one person finds difficult to live with, another might
better cope with. In this respect, it is pertinent to note
that the PFS-16 mean score for the total population
was 2.87, indicating that while one-third of patients
(33.8%) reported distressing fatigue (score .3.3), a
higher percentage probably had some fatigue present
but believed that they could cope with it. In addition,
we also acknowledge that the PFS-16 focuses on the
physical aspects of fatigue and therefore may have
Table 2 Factors associated with distressing fatigue
PFS-16 <3.3 PFS-16 ‡3.3 p Value
Total UPDRS score 28.8 6 15.5 43.9 6 20.6 ,0.0001
PDQ-39 score 45.7 6 12.3 64.1 6 14.7 ,0.0001
PWS score 358.1 6 44.1 329.5 6 44.7 ,0.0001
BDI score 8.9 6 6.8 15.6 6 8.0 ,0.0001
Total PDSS score 109.2 6 24.9 90.8 6 24.7 ,0.0001
PDSS item 15 score (daytime sleepiness) 7.8 6 2.8 6.5 6 3.4 ,0.001
Abbreviations: BDI 5 Beck Depression Inventory; PDQ-39 5 39-item Parkinson’s Disease Questionnaire; PDSS 5
Parkinson’s Disease Sleep Scale; PFS-16 5 16-item Parkinson’s Fatigue Scale; PWS 5 Psychological Well-being Scale;
UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Data are mean 6 SD.
Table 3 Logistic regression analysis of factors associated with fatigue
Covariate OR
95% Wald
confidence limits p Value
Preplanned analyses (n 5 343)
Sex (women) 1.781 1.026–3.092 0.040
Depression (yes) 3.137 1.228–8.012 0.017
Sleep disorders (yes) 1.833 1.050–3.199 0.033
Total UPDRS scorea 1.039 1.018–1.059 0.0002
Post hoc analyses (n 5 319)
UPDRS, activities of daily livinga 1.06 1.008–1.124 0.0237
PDQ-39, mobilitya 1.05 1.034–1.064 ,0.0001
Abbreviations: OR 5 odds ratio; PDQ-39 5 39-item Parkinson’s Disease Questionnaire;
UPDRS 5 Unified Parkinson’s Disease Rating Scale.
aOR can be interpreted as the odds of having fatigue for every 1-unit increase in the
predictive factor.
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underestimated clinically relevant emotional, cogni-
tive, or social aspects of fatigue.16
While it is generally held that there is no relation-
ship between the severity of motor dysfunction and
fatigue,2 the results of this study showed that higher
total UPDRS, UPDRS activities of daily living, and
PDQ-39 mobility scores were all associated with
fatigue, and that scores for individual motor items
were consistently higher in patients with distressing
fatigue compared to those without. These findings
indicate that fatigue worsens with the underlying dis-
ease progression, and are in agreement with recent
studies conducted in Italy19 and in Norway.3 This
study did not specifically assess whether the presence
of motor complications increased the likelihood of
distressing fatigue, but it might be expected because
the prevalence of motor complications also increases
with disease duration and severity.20 Notably, the
Norwegian study also found that female sex is predic-
tive of fatigue.3 It is not clear why women might be
more prone to fatigue than men; however, studies
conducted in patients affected by psychiatric disor-
ders have also found that the prevalence of fatigue is
higher in women.21 Similarly, while it is unclear why
patients with PD who have a lower educational status
may be more likely to have distressing fatigue, studies
of fatigue in multiple sclerosis (MS) have also re-
ported a strong correlation.22
This study serves to highlight the need to identify
and treat fatigue in PD. However, the management of
fatigue in PD still poses a significant problem in clin-
ical practice. For example, a study conducted in a
movement disorders center found that neurologists
failed to identify fatigue in more than half of the cases
and that the diagnostic accuracy for this symptom was
only 25%.23 The pharmacologic treatment of fatigue
in PD is also difficult, but clinical studies have shown
that treatment with levodopa24 and methylpheni-
date25 can improve fatigue. Results for the MAO-B
inhibitor rasagiline have been mixed, with one ran-
domized trial showing a benefit26 whereas another
smaller study failed to find a significant effect.27
Other studies in patients with PD have found that
fatigue is not influenced by dopamine agonists.28 In
our study, there were no substantial differences in
PFS-16 mean scores when grouping patients accord-
ing to their current antiparkinsonian medications.
This is in line with previous studies that have found
that the level of fatigue between drug-naive patients
and those treated with antiparkinsonian agents was
similar.29 However, in our study, proportionately
more patients without distressing fatigue (n 5 153)
were taking an MAO-B inhibitor with either levo-
dopa or a dopamine agonist than in the fatigued
group (n 5 52). By contrast, the proportion of
patients taking levodopa plus entacapone was higher
in the group of patients with fatigue compared with
the group without distressing fatigue. It is important
to note, however, that the levodopa plus entacapone
combination was used more frequently in patients
with more severe PD, while the rate of patients trea-
ted with levodopa and an MAO-B inhibitor did not
substantially differ between PD severity grades.
Despite the reported strong correlation of distress-
ing fatigue with depression and sleep disturbances,
most studies agree that all 3 are independent symp-
toms,2 and there is currently much interest in whether
they share pathophysiologic mechanisms. Similar
associations are known in patients with MS,30–32
and the treatment of depression has been shown to
improve the symptoms of fatigue in patients with
MS.31 Whether the treatment of fatigue improves
depressive symptoms has not been well studied. It is
therefore of considerable interest whether manage-
ment of these common nonmotor symptoms will
improve the symptoms of fatigue in patients with
PD. Notably, in MS and other diseases, fatigue, sleep
disturbances, and depression have also been shown to
“symptom cluster” with cognitive impairment,32 and
a limitation of the present study is that it does not
address fatigue in patients with PD who have demen-
tia and might have had difficulty in reporting their
symptoms of fatigue.
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